A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Actinic Keratosis
Interventions
DRUG

LEO 43204 Formulation 1

DRUG

LEO 43204 Formulation 2

DRUG

LEO 43204 Formulation 1 Dose X

DRUG

LEO 43204 Formulation 1 Dose Y

DRUG

LEO 43204 Formulation 2 Dose XX

DRUG

LEO 43204 Formulation 2 Dose YY

DRUG

Placebo Formulation 1

DRUG

Placebo Formulation 2

Trial Locations (25)

10029

Mount Sinai School of Medicine, New York

20850

DermAssociates, PC, Rockville

32174

Leavitt Medical Associates of Florida, Ormond Beach

33612

Clinical Research Center, Morsani Center for Advanced Healthcare, Tampa

47713

Research Institute of Deaconess Clinic, Evansville

47714

Hudson Dermatology, LLC, Evansville

48322

Henry Ford Medical Center, Dept. of Dermatology, West Bloomfield

48706

Great Lakes Research Group, Inc., Bay City

78229

Clinical Trials of Texas, Inc., San Antonio

85018

Omni Dermatology, Phoenix

90717

Torrance Clinical Research Institute Inc., Lomita

92121

Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc., San Diego

07044

The Dermatology Group, P.C., Verona

T5K 1X3

Stratica Medical Inc., Edmonton

V3R 6A7

Guildford Dermatology Specialists, Surrey

E1C 8X3

Durondel C.P. Inc./Dermatology Clinic, Moncton

L4M 6L2

Ultranova Skincare, Barrie

L1E 3C3

Co-Medica Research Network Inc., Courtice

L8N 1V6

Dermatrials Research Incorporated, Hamilton

N6A 3H7

The Guenther Dermatology Research Centre, London

L3P 1A8

Lynderm Research Inc., Markham

K9J 1Z2

SKiN Centre for Dermatology, Peterborough

N2J 1C4

K. Papp Clinical Research, Waterloo

N8W 1E6

XLR8 Medical Research, Windsor

G1V 4X7

Centre de Recherche Dermatologique du Quebec Metropolitain, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LEO Pharma

INDUSTRY